Genmab A/S (GMAB)
| Bid | 21.02 |
| Market Cap | 13.13B |
| Revenue (ttm) | 21.53B |
| Net Income (ttm) | 7.84B |
| EPS (ttm) | 1.84 |
| PE Ratio (ttm) | 11.44 |
| Forward PE | 1.51 |
| Analyst | Buy |
| Ask | 21.05 |
| Volume | 490,900 |
| Avg. Volume (20D) | 1,490,396 |
| Open | 21.31 |
| Previous Close | 21.15 |
| Day's Range | 20.98 - 21.30 |
| 52-Week Range | 17.23 - 30.41 |
| Beta | 0.96 |
About GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esoph...
Analyst Forecast
According to 9 analyst ratings, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is $41, which is an increase of 94.82% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Genmab: GEN3014's Demise And Implications For The HexaBody PlatformGenmab's stock fell after J&J opted out of developing GEN3014 due to its undifferentiated efficacy and worse safety and tolerability compared to Darzalex. Genmab wisely chose not to pursue GEN3014 fur...
1 month ago · businesswire.com
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop,...
2 months ago · seekingalpha.com
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming SoonGenmab reported strong Q4 2024 results, with $897.4 million in revenue, beating expectations and showing 29% Y/Y growth, driven by Darzalex royalties. 2025 revenue guidance was slightly ahead of conse...